Company intelligence / Profile preview

Regentis Biomaterials

Herzliya, Tel Aviv District, Israelregentis.co.il ↗
Ownership
Private
Employees
~3
Development stage
Phase 3
01

Overview

Regentis Biomaterials has developed GelrinC, a cell-free hydrogel implant for articular cartilage repair. The product has demonstrated promising results in European clinical trials—showing improvement in pain and function—and received CE mark approval. In the US, it remains investigational and under evaluation through expanded SAGE clinical trials at multiple sites. The technology leverages a unique blend of polyethylene glycol diacrylate and denatured fibrinogen to create an off-the-shelf scaffold that supports endogenous stem cell-driven regeneration.

Therapeutic areas
Rheumatology
Modalities
Device (hydrogel implant)Hydrogel-based drug delivery therapyBiologic (denatured fibrinogen component)Polymer-drug conjugate therapy (polyethylene glycol diacrylate/fibrinogen matrix)
Industry
Implantable Medical Devices
02

Drug pipeline

1 asset

GelrinC

Unknown
03

Partnerships

No major pharma partnerships disclosed; seeking strategic partners for commercialization especially in Europe.

Beyond the preview

Go deeper on Regentis Biomaterials.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regentis Biomaterials.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call